Complain about a product or service

GlaxoSmithKline Settles Paxil Lawsuit

March 29, 2006

• Parties Settle Paxil "Split Pill" Class Action • Improved Paxil Settlement Hits YouTube • Bigger Settlement for Paxil Parents • GlaxoSmithKline Settles Paxil Lawsuit • FDA Warns Paxil Users of Birth Defect Risk • Study Finds Stronger Link Between Paxil And Suicide • Paxil CR Back on Pharmacy Shelves • SmithKline to Pay $65 Million to Settle Paxil Antitrust Case • Glaxo Misled Doctors About Safety of Paxil, NY Charges --- • Consumer Complaints about Paxil

GlaxoSmithKline has agreed to pay $14 million to resolve a multistate legal action that claims it wrongfully delayed generic competition for Paxil, its blockbuster drug used to treat depressive, anxiety, and obsessive-compulsive disorders.

The settlement resolves claims by 49 states that charged their Medicaid programs had been gouged. In August 2004, New York Attorney General Eliot Spitzer reached a separate agreement with GSK under which the company became the first major drug manufacturer to publicly disclose information on clinical studies of its drugs.

Spitzer's settlement followed a lawsuit alleging that the company withheld negative information suggesting a possible increased risk of suicidal thinking and acts in certain individuals taking Paxil.

In April 2005, Spitzer reached a second unrelated national settlement with GSK for $10 million. It was designed to resolve state claims that GSK delayed generic competition by fraudulently listing and prosecuting litigation concerning the drug nabumetone, an anti-inflammatory drug that GSK sells under the trademark Relafen.

Proceeds from the settlement will be distributed among the states.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Follow us on Twitter.